MDM2 antibody
GTX100531
ApplicationsImmunoFluorescence, ImmunoPrecipitation, Western Blot, ChIP Chromatin ImmunoPrecipitation, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman, Mouse
TargetMDM2
Overview
- SupplierGeneTex
- Product NameMDM2 antibody
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. IP: 1:100-1:500. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoFluorescence, ImmunoPrecipitation, Western Blot, ChIP Chromatin ImmunoPrecipitation, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration0.68 mg/ml
- ConjugateUnconjugated
- Gene ID4193
- Target nameMDM2
- Target descriptionMDM2 proto-oncogene
- Target synonymsACTFS, HDMX, LSKB, hdm2, E3 ubiquitin-protein ligase Mdm2, MDM2 oncogene, E3 ubiquitin protein ligase, MDM2 proto-oncogene, E3 ubiquitin protein ligase, Mdm2, p53 E3 ubiquitin protein ligase homolog, Mdm2, transformed 3T3 cell double minute 2, p53 binding protein, double minute 2, human homolog of; p53-binding protein, oncoprotein Mdm2
- HostRabbit
- IsotypeIgG
- Protein IDQ00987
- Protein NameE3 ubiquitin-protein ligase Mdm2
- Scientific DescriptionThis gene is a target gene of the transcription factor tumor protein p53. The encoded protein is a nuclear phosphoprotein that binds and inhibits transactivation by tumor protein p53, as part of an autoregulatory negative feedback loop. Overexpression of this gene can result in excessive inactivation of tumor protein p53, diminishing its tumor suppressor function. This protein has E3 ubiquitin ligase activity, which targets tumor protein p53 for proteasomal degradation. This protein also affects the cell cycle, apoptosis, and tumorigenesis through interactions with other proteins, including retinoblastoma 1 and ribosomal protein L5. More than 40 different alternatively spliced transcript variants have been isolated from both tumor and normal tissues. [provided by RefSeq]
- ReactivityHuman, Mouse
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Tateishi K, Miyake Y, Nakamura T, et al. Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma. Acta Neuropathol Commun. 2023,11(1):186. doi: 10.1186/s40478-023-01683-xRead this paper
- Cheng HC, Huang PH, Lai FJ, et al. Loss of fragile WWOX gene leads to senescence escape and genome instability. Cell Mol Life Sci. 2023,80(11):338. doi: 10.1007/s00018-023-04950-1Read this paper
- Zeng M, Chen Y, Jia X, et al. The Anti-Apoptotic Role of EBV-LMP1 in Lymphoma Cells. Cancer Manag Res. 2020,12:8801-8811. doi: 10.2147/CMAR.S260583Read this paper
- Zheng H, Yang G, Fu J, et al. Mdm2 Promotes Odontoblast-like Differentiation by Ubiquitinating Dlx3 and p53. J Dent Res. 2020,99(3):320-328. doi: 10.1177/0022034519893672Read this paper
- Tseng CW, Kuo WH, Chan SH, et al. Transketolase Regulates the Metabolic Switch to Control Breast Cancer Cell Metastasis via the α-Ketoglutarate Signaling Pathway. Cancer Res. 2018,78(11):2799-2812. doi: 10.1158/0008-5472.CAN-17-2906Read this paper
- Briest F, Grass I, Sedding D, et al. Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors. Neuroendocrinology. 2018,107(1):1-23. doi: 10.1159/000481506Read this paper
- Liu Y, Dai L, Liu W, et al. Autoantibody to MDM2: A Potential Serological Marker of Systemic Lupus Erythematosus. J Immunol Res. 2015,2015:963568. doi: 10.1155/2015/963568Read this paper
- Chai Y, Peng B, Dai L, et al. Autoantibodies response to MDM2 and p53 in the immunodiagnosis of esophageal squamous cell carcinoma. Scand J Immunol. 2014,80(5):362-8. doi: 10.1111/sji.12202Read this paper




